There are both advantages and disadvantages for financial VCs considering a co-investment by a corporate venture investor. The pros include, the ability to draw on the extensive due diligence resources of the corporate parent company; benefiting from the corporate VC's skills at evaluating later stage risk; and the corporate VC's perspective of the customer. On the downside, the unpredictability of corporate VCs' ability to make follow-on investments; different expectations on returns; and potential conflicts-of-interest. In general, though corporate VC investment is a very good thing, and any associated negatives can be handled through the structuring of the relationship and by making sure that there are consistent expectations on both sides.
Question: How do institutional venture capitalists regard the
proposed investment by a corporate venture fund in a later (Series
B or after) financing round of a biotech or medical device
company?
Answer: Corporate venture funds have different missions and thus employ different investment practices. That makes it difficult to generalize institutional venture funds' reaction to the introduction of a corporate player...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.
Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.
Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.